Literature DB >> 16029373

Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma.

M Baltaci, P Fritsch, F Weber, A Tzankov, P Sögner, A M Derler, R Höpfl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16029373     DOI： 10.1111/j.1365-2133.2005.06709.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  7 in total

1.  A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Authors:  Carol M Lewis; Bonnie S Glisson; Lei Feng; Fiona Wan; Ximing Tang; Ignacio I Wistuba; Adel K El-Naggar; David I Rosenthal; Mark S Chambers; Robert A Lustig; Randal S Weber
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

2.  Management of high-risk cutaneous squamous cell carcinoma.

Authors:  Lorraine Jennings; Chrysalyne D Schmults
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

Review 3.  Management of High-Risk Squamous Cell Carcinoma of the Skin.

Authors:  Teresa Fu; Sumaira Z Aasi; S Tyler Hollmig
Journal:  Curr Treat Options Oncol       Date:  2016-07

4.  Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.

Authors:  C Hope Heath; Nicholas L Deep; Lisle Nabell; William R Carroll; Renee Desmond; Lisa Clemons; Sharon Spencer; J Scott Magnuson; Eben L Rosenthal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-22       Impact factor: 7.038

Review 5.  Therapy of advanced squamous cell carcinoma of the skin.

Authors:  Claudia Bejar; Eve Maubec
Journal:  Curr Treat Options Oncol       Date:  2014-06

6.  Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases.

Authors:  William L Read; Kevin T Brumund; Robert A Weisman; Angel Q Nguyen
Journal:  JAAD Case Rep       Date:  2015-05-25

Review 7.  Novel Therapeutic Targets in Cutaneous Squamous Cell Carcinoma.

Authors:  Teruki Yanagi; Shinya Kitamura; Hiroo Hata
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.